Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report
Radiation Oncology, ISSN: 1748-717X, Vol: 6, Issue: 1, Page: 94
2011
- 26Citations
- 42Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes26
- 26
- CrossRef17
- Captures42
- Readers42
- 42
Article Description
A patient with anaplastic meningioma and lung metastases resistant to conventional treatment underwent radiopeptide therapy with 177Lu- DOTA-octreotate in our institute. The treatment resulted in significant improvement in patient's quality of life and inhibition of tumor progression. This case may eventually help to establish the value of radiopeptide therapy in patients with this rare condition. © 2011 Sabet et al; licensee BioMed Central Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80051600792&origin=inward; http://dx.doi.org/10.1186/1748-717x-6-94; http://www.ncbi.nlm.nih.gov/pubmed/21835043; https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-6-94; http://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-6-94; https://dx.doi.org/10.1186/1748-717x-6-94
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know